Brokerages Anticipate Clearside Biomedical Inc (CLSD) Will Announce Earnings of -$0.36 Per Share
Wall Street brokerages forecast that Clearside Biomedical Inc (NASDAQ:CLSD) will report ($0.36) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Clearside Biomedical’s earnings. The highest EPS estimate is ($0.24) and the lowest is ($0.56). Clearside Biomedical reported earnings of ($0.62) per share during the same quarter last year, which would indicate a positive year over year growth rate of 41.9%. The business is expected to announce its next quarterly earnings report on Wednesday, May 8th.
On average, analysts expect that Clearside Biomedical will report full-year earnings of ($1.35) per share for the current year, with EPS estimates ranging from ($1.83) to ($0.79). For the next financial year, analysts expect that the company will report earnings of ($0.89) per share, with EPS estimates ranging from ($1.21) to ($0.69). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Clearside Biomedical.
Clearside Biomedical (NASDAQ:CLSD) last released its earnings results on Tuesday, March 12th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.13). The firm had revenue of $0.03 million during the quarter.
Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new position in shares of Clearside Biomedical during the third quarter worth about $216,000. Virtu Financial LLC acquired a new position in Clearside Biomedical during the fourth quarter valued at approximately $57,000. Dimensional Fund Advisors LP acquired a new position in Clearside Biomedical during the third quarter valued at approximately $557,000. Fosun International Ltd acquired a new position in Clearside Biomedical during the fourth quarter valued at approximately $178,000. Finally, Alambic Investment Management L.P. acquired a new position in Clearside Biomedical during the fourth quarter valued at approximately $26,000. 35.49% of the stock is owned by institutional investors.
Shares of CLSD stock traded down $0.02 on Tuesday, reaching $1.24. 413,668 shares of the stock were exchanged, compared to its average volume of 626,976. The company has a debt-to-equity ratio of 0.40, a quick ratio of 4.10 and a current ratio of 4.10. Clearside Biomedical has a one year low of $0.99 and a one year high of $15.33.
About Clearside Biomedical
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.
See Also: What is a Leveraged Buyout (LBO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.